5 Biggest Genomics Companies In The World

In this article, we will discuss the 5 Biggest Genomics Companies In The World. If you want to read our analysis of the genomics market, you can head on to the 12 Biggest Genomics Companies In The World.

5. Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Market Capitalization: $3.95 billion

Number of Hedge Fund Holders: 27

Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a pioneer in the genome editing industry and has contributed to the discovery and development of CRISPR/Cas9 platform. It is capitalizing on its modular platform to bring about development in curative in vivo and Ex vivo treatments which have largely been neglected. The company is also running a program to develop Ex vivo treatments to counter auto-immune diseases.

On October 11, 2022, Terence Flynn, an analyst at Morgan Stanley, started coverage of Intellia Therapeutics, Inc. (NASDAQ:NTLA) with an Overweight rating and a price target of $84 on the company’s stock. In a research note to investors, the analyst stated that the company is one of the leading genome editing companies in the world and also the pioneer in the field. The analyst stated that the company has demonstrated its capability to turn off a gene and awaits data from the NTLA-3001 study, which has the potential to open up a bigger opportunity for the company.

Carillon Tower Advisers discussed its stance on Intellia Therapeutics, Inc. (NASDAQ:NTLA) in its Q2 2021 investor letter.

Intellia Therapeutics is a clinical-stage genome editing company focused on the development of proprietary, potentially curative therapeutics. The company’s stock soared after announcing positive interim data from an ongoing phase 1 clinical study of its in vivo gene editing candidate, which is being developed as a single-dose treatment for hereditary transthyretin (ATTR) amyloidosis. This specific form of therapy would be the first of its kind resulting in the precision editing of a gene in a target tissue in the human body.

At the end of the second quarter, 27 hedge funds in Insider Monkey database were bullish on the company. ARK Investment Management had an investment value of over $439 million in the company at the end of Q2 2022, making it the biggest stakeholder of the company.